The company's diverse pipeline of Treg-modulating candidates seeks to restore immune balance by targeting inflammation, a common and critical factor in the progression of numerous neurodegenerative diseases (NDDs) and autoimmune diseases. Coya aims to treat 1.7 million patients across the U.S., with a total addressable market exceeding $7 billion. Moreover, Coya recently reported encouraging results from its proof-of-concept study in ALS patients. COYA 302 effectively slowed disease progression, as demonstrated by a lack of decline at 24 weeks and minimal decline at 48 weeks after initiation of treatment in Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) scores compared to score values at baseline. A higher ALSFRS-R score represents better functional status in ALS patients. The positive clinical results were consistent with the increased Treg function observed over the treatment period.
